Navigation Links
Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
Date:5/30/2012

MORRISTOWN, N.J., May 30, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Nifedipine Extended-Release Tablets, USP, 90mg, a generic equivalent to Bayer's Adalat® CC.  Distribution of the product has commenced. 

Nifedipine Extended-Release Tablets, USP, 90mg has sales of approximately $23 million for the 12 months ending December 31, 2011, according to IMS Health.   

Commenting on the new approval, Mike Perfetto, Vice President of Sales & Marketing of Actavis Inc, said:

"The launch of Nifedipine Extended-Release Tablets, USP 90mg complements the Nifedipine Extended-Release 30mg and 60 mg tablets that we currently market.  It is yet another example of Actavis' expertise in developing complex extended release products."

About Actavis:
Actavis Inc. is the U.S. subsidiary of Actavis Group hf.  Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Adalat® CC is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statemen
'/>"/>

SOURCE Actavis Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
2. Watson to Acquire Actavis Group for EUR4.25 Billion
3. QRxPharma Signs License and Option Agreement with Actavis
4. Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
5. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
6. Actavis to Launch Novel Pain Medication in the US
7. QRxPharma Announces Strategic Partnership with Actavis
8. Actavis Launches Generic KADIAN® Capsules in the U.S.
9. Actavis Plans Latin America Expansion
10. Actavis Launches Generic Keppra XR® Tablets in the U.S.
11. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an ... for patients to self-inject prescription drugs in the large ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... expected to grow to $220B by 2018, according to ... type of injector that does not exist today for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... AMSTERDAM, October 8 BMEYE B.V., the non-invasive,cardiovascular ... B financing round, raising EUR 6 million. New investors,Earlybird, ... in the,financing, along with other existing BMEYE shareholders as ... BMEYE has successfully been selling Nexfin(TM), an FDA ...
... Oct. 8 Advanced Health Media, LLC (AHM) has ... and related technology for the pharmaceutical and life sciences ... in speaker bureau management, supplying automation and compliance management ... promotional events for more than 200 brands. The ...
Cached Medicine Technology:BMEYE B.V. Completes EUR 6 Million Series B Financing Round 2BMEYE B.V. Completes EUR 6 Million Series B Financing Round 3Advanced Health Media Announces Acquisition of Ephikacy, LLC 2Advanced Health Media Announces Acquisition of Ephikacy, LLC 3
(Date:4/14/2014)... NJ. April 10, 2014. John DeLuca, PhD, and Yael ... Idec to study how persons with multiple sclerosis (MS) ... of Actual Reality to Measure Everyday Life Functional Activity ... research. Dr. DeLuca is senior VP of Research & ... at New York University, is a visiting scientist at ...
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... COLUMBUS, Ohio A new study identifies a molecule ... and suggests that the molecule could be an important ... of tumor progression. , The study of microRNA-135b (miR-135b) ... in the journal Cancer Cell and was ... Cancer Center Arthur G. James Cancer Hospital and ...
(Date:4/14/2014)... --- Depression can hit young fathers hard -- with symptoms ... their children,s lives, a new Northwestern Medicine study has found. ... the first five years of fatherhood for these young men, ... and whom lived in the same home as their children. ... the journal Pediatrics . , This study is the ...
(Date:4/14/2014)... world, many people live and work in dim and ... And as the global population continues to rise and ... spread. , To alleviate the problem, Egyptian researchers ... onto narrow streets and alleyways. The panel is mounted ... angle, where it spreads sunlight onto the street below. ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
... Feb. 25 Omnicell, Inc.,(Nasdaq: OMCL ), a ... today that its Board of Directors has approved the,repurchase ... its Common Stock over,the next 12 months. The Company,s ... after a review of the Company,s financial position and,investment ...
... -- Up to 20 percent of patients taking aspirin ... event do not have an antiplatelet response from aspirin, ... at the University at Buffalo have shown. , ... of a second stroke, second heart attack or second ...
... HILL Bacteria mutate for a living, evading antibiotic drugs ... States each year. But as concern about drug-resistant bacteria grows, ... Carolina at Chapel Hill seeks to thwart the bug without ... Mark Schoenfisch and his lab of analytical chemists at UNC ...
... GmbH, a Systems Biology company focussed on high quality ... showcasing its abilities in the analysis of data generated ... Boyle et al published in the January 2008 issue ... of Open Chromatin across the Genome where they identified ...
... 25 Danaher Corporation,(NYSE: DHR ) announced ... Jr. will be presenting at the Citigroup Global ... March 5 at 8:00,a.m. EST. The audio will ... will be archived on, http://www.danaher.com for one ...
... new blockages within 3 years, study finds , , ... a blood clot in their legs (deep vein thrombosis) ... of developing another blood clot within three years, a ... embolism are known collectively as venous thromboembolism. , Researchers ...
Cached Medicine News:Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 2Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 3Health News:Many stroke, heart attack patients may not benefit from aspirin 2Health News:Many stroke, heart attack patients may not benefit from aspirin 3Health News:Silica smart bombs deliver knock-out to bacteria 2Health News:Genomatix integrates genome-wide open chromatin from next generation sequencing 2Health News:Blood Clots in Legs, Lungs Predispose Patients to Repeat Episodes 2
... Technology, multi-frequency, linear micro-surgery transducer. ... very helpful in tight situations. ... a choice transducer for pediatric ... high frequency upper end makes ...
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
Super High Density, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit. Change frequencies on the fly for deeper penetration or for superficial n...
Medicine Products: